Vicat


Q3: Pricing drives sales but not margins

09/11/26 -"Vicat reported Q3 organic sales growth of 10.2%, well above the 6.8% expected by consensus, supported by strong performance in Asia-Mediterranean and Africa. Management raised FY26 sales guidance to ..."

Pages
62
Language
English
Published on
09/11/26
You may also be interested by these reports :
09/11/26
Vicat reported Q3 organic sales growth of 10.2%, well above the 6.8% expected by consensus, supported by strong performance in Asia-Mediterranean and ...

06/11/26
Our revised sum-of-the-parts values Imerys’ core divisions broadly in line with the group’s current trading multiple of approximately 7x EBITDA, with ...

04/11/26
Heidelberg Materials reported Q3 revenue and RCO 3.5% and 3.6% above consensus, confirmed FY26 guidance and announced another €300m of cost savings. ...

03/11/26
Geberit’s Q3 results were broadly in line, with sales up 5.2% in local currencies and EBITDA margin at 30.2%, down 40bp year-on-year. Guidance ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO